Press release - 09/11/2022 New Molecular Microscopy Uncovers how Breast Cancer Spreads Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
Press release - 02/11/2022 The guardian of the (epi-)genome Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 19/10/2022 Molecular structure of one of the most important receptors in the immune system unraveled Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
Press release - 05/10/2022 Second Stem Cell Type Discovered in Mouse Brain In the brain of adult mammals neural stem cells ensure that new nerve cells, i.e. neurons, are constantly formed. This process, known as adult neurogenesis, helps mice maintain their sense of smell. A research team led by Dr Francesca Ciccolini at the Interdisciplinary Center for Neurosciences (IZN) of Heidelberg University recently discovered a second stem cell population in the mouse brain. https://www.gesundheitsindustrie-bw.de/en/article/press-release/zweiter-stammzelltyp-im-maeusehirn-entdeckt
Press release - 01/09/2022 Personalised antibiotic treatment strategies for tuberculosis patients Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
Press release - 03/06/2022 Deep Learning helps improve gene therapies and antiviral drugs The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
Press release - 12/05/2022 New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
Press release - 28/04/2022 Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
Press release - 25/04/2022 Reprogrammed macrophages promote spread of breast cancer Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
Peptide-based COVID-19 vaccine - 21/04/2022 CoVac-1: T-cell activator against COVID-19 Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Press release - 02/03/2022 HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Antibiotic detection from whole blood or exhaled breath possible Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
Press release - 11/01/2022 Obesity at a young age - a risk factor for early colorectal cancer The incidence of colorectal cancers in young adults is increasing. At the same time, the proportion of overweight and obese young people is also on the rise. Whether there is a connection between these two observations, however, was not known until now. Scientists at the DKFZ have now shown that the risk of early colorectal cancer is significantly increased in overweight young people compared to normal-weight peers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/obesity-young-age-risk-factor-early-colorectal-cancer
Press release - 20/12/2021 Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
Dossier - 16/12/2021 Advanced therapy medicinal products: gene and cell therapies Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.https://www.gesundheitsindustrie-bw.de/en/article/dossier/advanced-therapy-medicinal-products-gene-and-cell-therapies
Press release - 09/12/2021 New research project in mathematical oncology A new interdisciplinary research project aims to uncover information that can help decode hereditary colon cancer with the aid of mathematical models. Mathematicians and tumour biologists of Heidelberg University, the Heidelberg Institute for Theoretical Studies, Heidelberg University Hospital, and the German Cancer Research Center are collaborating on the project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-project-mathematical-oncology
Cluster of the future - 25/11/2021 nanodiagBW: using nanopores to create completely new diagnostic possibilities Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 18/11/2021 Overcoming resistance to treatment for breast, bowel, and pancreatic cancer As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
Funding EU4Health- Programme Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027 https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
Optimised peptides against infections and cancer - 07/10/2021 New bioactive ingredients from the peptidome treasure chest Peptides are increasingly coming into scientific focus for application in diagnostics and therapy. The human body is full of these protein fragments, but only a fraction have been characterised. So there is enormous potential for discovering new biologically active substances that can help in the fight against bacteria, viruses and cancer. A collaborative research centre at Ulm University Hospital is on the trail of these promising fragments.https://www.gesundheitsindustrie-bw.de/en/article/news/new-bioactive-ingredients-peptidome-treasure-chest